NCT06768255View on ClinicalTrials.gov

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

June 30, 2029

Conditions
Abiraterone AcetateMCRPC (metastatic Castration-resistant Prostate Cancer)
Interventions
DRUG

Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT

Abiraterone Acetate（II）

DRUG

Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT

Abiraterone acetate 1000 mg

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Ding-Wei Ye

OTHER